Bitterman and Brownlie join board at RXi
This article was originally published in Scrip
RNAi therapeutics company RXi Pharmaceuticals has appointed Robert Bitterman and Keith Brownlie to its board of directors. Mr Bitterman currently serves as president and CEO of Cutanea Life Sciences, a wholly owned subsidiary of Maruho Company. Mr Brownlie joins RXi following a 36-year career at Ernst & Young. For the last 20 years before his retirement in 2010, he was Metro New York Area Life Sciences Industry Leader at the company. Mr Brownlie also serves on the boards of Epicept and Soligenix.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.